Cell therapy, one of the most promising frontiers in modern medicine, holds the potential to cure once-incurable diseases such as cancer and genetic disorders. But for all its promise, manufacturing ...
As the CGT market evolves, developers must answer one key question that will shape their manufacturing strategy: “Should we go with a modular platform or a fully integrated system?” Both approaches ...
- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...
SOUTH SAN FRANCISCO, Calif. & MADISON, Wis.-- (BUSINESS WIRE)--Feb 18, 2026-- ...
The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help ...
Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...
In this innovation spotlight, Tia Harmon, technical science liaison, CGT for PHC Corporation of North America (PHCNA), discusses the key challenges in CGT manufacturing and how in-line monitoring ...
Hosted on MSN
Laser-based analytical platform enhances CAR T cell therapy manufacturing and effectiveness
A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor (CAR) T cells, including how they evolve during manufacturing and ...
Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results